AbCellera Biologics Inc.
ABCL
$10.89
-$0.09-0.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -59.61% | 5.38% | 73.85% | -11.76% | 5.97% |
| Total Depreciation and Amortization | 24.41% | 31.04% | 143.76% | -81.10% | -81.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.32% | -15.35% | -57.49% | 249.17% | 152.37% |
| Change in Net Operating Assets | 431.16% | -228.10% | -410.17% | -216.58% | -109.10% |
| Cash from Operations | 180.00% | -190.14% | -334.29% | -82.10% | -8.14% |
| Capital Expenditure | 84.05% | 63.98% | 37.02% | 51.78% | 33.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.04% | -214.43% | 65.55% | 104.45% | -125.55% |
| Cash from Investing | 135.65% | -416.08% | 110.45% | 886.70% | -161.06% |
| Total Debt Issued | -20.47% | 20.47% | 143.67% | 126.91% | -310.66% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 423.51% | -- | -3,520.90% | 1.09% | 1,518.03% |
| Cash from Financing | 289.42% | 20.47% | -0.65% | 134.40% | -227.31% |
| Foreign Exchange rate Adjustments | -156.50% | -106.44% | 113.43% | -248.23% | 1,869.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 164.68% | -1,849.40% | 50.92% | 57.19% | -370.13% |